Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...

Many people on these weight-loss drugs - which include Ozempic, Wegovy, Zepbound and Mounjaro ... as research firms that track consumer spending are already finding. For example, Impact Analytics ...

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...